Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

Recall Merck also tried to get an "improved

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
genisi Member Profile
 
Followed By 31
Posts 5,128
Boards Moderated 0
Alias Born 05/24/06
160x600 placeholder
Big Homes Can Complicate Retirement
Once you've paid for your house, how much will it cost you?
China Mobile's Need for Speed -- Barron's Asia
Technip Bids for CGG -- 2nd Update
Zoetis Unveils $500 Million Stock Buyback Plan -- Update
Intel Projects More Growth in 2015 -- Update
Appeals Court Grants TV Programmers Stay in FCC Dispute -- Update
Wireless Carriers Bid Up US Airwaves To Record
Two Top-Producing Advisers Leave Merrill Lynch--Street Moves
Chinese Premier Plays Down Qualcomm's Woes
Activision Blizzard to Get $275 Million in Settlement
genisi   Wednesday, 04/27/11 03:49:51 AM
Re: biomaven0 post# 118902
Post # of 184126 
Recall Merck also tried to get an "improved niacin" by targeting the same receptor with MK-0354, which despite significant decreases in FFAs levels and absence of flushing failed to demonstrate effects on HDL/LDL-Cholesterol and TGs in phase II. Obviously, being a GPR109A receptor agonist isn't all.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist